StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) bonds

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Total debt
$393.27M
$89.00K due within a year
Net debt
–
Implied interest rate
14.99%
FY2025 interest ÷ average debt
Interest coverage
0.8×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Caris Life Sciences's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issued
2018 Convertible Notes
Convertible
8.00%$50.00M
2025 Convertible Notes
Convertible
8.00%$30.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawnExpires
2026 Term Loan$400.00M–2026
2023 Term Loan Initial Draw - January 18, 2023–$0–
2023 Term Loan Subsequent Draw - March 5, 2024–$0–
2026 Term Loan Initial Draw - April 1, 2026–$400.00M–
Delayed Term Loan Facility$300.00M––
Exit fee on 2023 Term Loan - January 18, 2023–$0–
Exit fee on 2023 Term Loan - March 5, 2024–$0–

See a number that looks wrong?